Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Prenen, Hans

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. [electronic resource] - Oncotarget Nov 2015 - 36418-25 p. digital

Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.5503 doi


Antineoplastic Agents--therapeutic use
Cytogenetics
Female
Hemangiosarcoma--drug therapy
Humans
Indoles--therapeutic use
Liver Neoplasms--drug therapy
Middle Aged
Mutation
Phospholipase C gamma--genetics
Pyrroles--therapeutic use
Signal Transduction
Sunitinib